Notifications
Clear all

Testosterone Undecanoate (Nebido/Aveed): Long

Danielle Strickland
(@danielle-strickland)
New Member

Complete guide to testosterone undecanoate (Nebido/Aveed) for TRT: injection schedules, dosing protocols, steady-state timelines, and managing 10-14 week

Men with total testosterone below 300 ng/dL experience 33% higher all-cause mortality over 20 years compared to those above 550 ng/dL (European Heart Journal, 2013). Testosterone undecanoate—branded as Nebido in Europe and Aveed in the United States—offers a radically different protocol: 1000mg injections every 10–14 weeks instead of the twice-weekly pinning required by cypionate or enanthate. This long-acting ester dissolves in castor oil and releases testosterone gradually through a depot mechanism. The question is whether convenience justifies the trade-offs in metabolic stability and dosing flexibility.

Testosterone undecanoate uses an exceptionally long carbon chain—11 carbons versus 8 for cypionate and 7 for enanthate. The half-life reaches 33.9 days according to Bayer’s Phase III trials (Journal of Clinical Endocrinology & Metabolism, 2004). This extended release profile means a single 1000mg intramuscular injection maintains therapeutic testosterone levels for 12 weeks in 87% of patients.

Peak serum testosterone occurs 7–14 days post-injection, typically reaching 800–1200 ng/dL. Trough levels at week 10–12 usually stabilize between 400–600 ng/dL. A 2014 study in Andrology tracking 1,438 men over 5 years found mean trough testosterone of 493 ng/dL with a standard deviation of 141 ng/dL. The coefficient of variation sits around 29%—acceptable for maintaining physiologic levels but problematic for men seeking tight control.

The castor oil vehicle creates an intramuscular depot that releases testosterone undecanoate into lymphatic circulation before hepatic conversion to free testosterone. Injection volume is 4mL delivered via 21-gauge needle into the gluteus medius. This is not a subcutaneous protocol.

Testosterone undecanoate serves specific patient populations where injection frequency is the primary barrier to compliance.


Quote
Topic starter Posted : 07/11/2025 4:40 pm
Justin Long
(@justin-long)
New Member

my experience with low dose vs high dose primobolan


ReplyQuote
Posted : 08/11/2025 1:40 am
Daniel Marshall
(@daniel-marshall)
New Member

how to handle the ”anadrol lethargy” during a heavy bulk


ReplyQuote
Posted : 08/11/2025 5:40 am
Jeffrey James
(@jeffrey-james)
New Member

the difference between human grade vs underground lab gear


ReplyQuote
Posted : 08/11/2025 5:40 pm
Share: